Peptide Regulation Is Changing.
Here's What Actually Matters.
Votes, headlines and regulatory language can make this harder than it needs to be. We track what changed, what didn't, and what happens next.
Three quick answers
PCAC voted.
In July 2026, FDA's advisory committee recommended six of seven peptide substances reviewed for possible inclusion on the 503A Bulks List.
Recommendation ≠ approval.
The committee's vote is advisory. It did not make these peptides FDA-approved drugs and did not itself authorize compounding.
FDA decides.
FDA must determine what action to take. Additional peptides are also scheduled for PCAC review before the end of February 2027.
A vote is a step. Not the finish line.
The July hearing was meaningful, but the language matters.
PCAC is an advisory committee. It gives FDA scientific and technical recommendations. FDA is not legally bound by those votes. A favorable recommendation for the 503A Bulks List is also not the same thing as FDA approval of a drug for safety and effectiveness.
What the committee recommended.
Six substances received favorable recommendations. Emideltide did not. The votes were close — which is part of the story.
What happens from here?
There are still regulatory steps between an advisory vote and a durable compounding pathway.
PCAC review completed
The committee reviewed seven peptide-related bulk drug substances for possible 503A Bulks List inclusion and made non-binding recommendations.
FDA considers the recommendations
FDA reviews the committee's advice and determines what regulatory action to take. Until FDA acts, a committee vote should not be described as FDA approval.
Five more substances scheduled for review
FDA has announced future PCAC consideration of GHK-Cu, LL-37, Dihexa acetate, Melanotan II and PEG-MGF.
Rules, policy and enforcement continue to evolve
503A, 503B, approved-drug status and research-use markets are different regulatory lanes. We'll keep them separate rather than collapse them into a single "legal / illegal" label.
Read more. Decide for yourself.
We'll explain the landscape, but you should be able to inspect the underlying material too.
The July 2026 FDA Hearing
Our deeper explanation of the PCAC process, the compounds reviewed and what the hearing means.
Read the hearing guideResearch Reference Library
Primary-source research, FDA documentation and supporting references collected in one place.
View the sourcesFDA Meeting Materials
Agenda, briefing documents, presentations and official materials directly from FDA.
Go to FDA.govReVia is on the federal record.
ReVia LLC submitted formal written comments to FDA's Pharmacy Compounding Advisory Committee and participated in the July 2026 public hearing. We believe better decisions begin with better information — including information from regulators, researchers, practitioners, manufacturers and the people already navigating this market.
Our written comments
Docket FDA-2025-N-6895
Document ID FDA-2025-N-6895-0001
That depends on what you're looking for.
Whether you want to explore peptides, dig deeper into the research, build a practitioner program, or discuss supply — we'll help you find the right next step.
Know more.
Useful research, regulatory updates and resources worth knowing about.
Thanks — you're on the list.
No spam. Unsubscribe anytime.